Evidence map›Paper›PMID 27034851›Full record

ArticleNeural plasticity2016

Nucleolar PARP-1 Expression Is Decreased in Alzheimer's Disease: Consequences for Epigenetic Regulation of rDNA and Cognition.

Jianying Zeng, Jenny Libien, Fatima Shaik, Jason Wolk, A Iván Hernández

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neural plasticity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Role of NADCellular and molecular neurobiology · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Sobriety and Satiety: Is NAD+ the Answer?Antioxidants (Basel, Switzerland) · 2020
    Review
  17. Review
  18. Contributions of DNA Damage to Alzheimer's Disease.International journal of molecular sciences · 2020
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jianying ZengDepartment of Pathology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA.
Jenny LibienDepartment of Pathology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA; Department of Neurology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA.
Fatima ShaikDepartment of Pathology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA.
Jason WolkDepartment of Physics, New York University, New York, NY 10003, USA.
A Iván HernándezDepartment of Pathology, State University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA; The Robert F. Furchgott Center for Neural and Behavioral Science, State University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA.
State University of New York · USNew York University · USSUNY Downstate Health Sciences University · US

Funding

Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
National Brain and Tissue Resource for Parkinson's Disease and Related DisordersU24NS072026 · NINDS · BANNER SUN HEALTH RESEARCH INSTITUTE · PI BEACH, THOMAS G · 2011 to 2015
$7.8M
NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG19610NINDS NIH HHS U24 NS072026
6 · The paper itself

Abstract

Synaptic dysfunction is thought to play a major role in memory impairment in Alzheimer's disease (AD). PARP-1 has been identified as an epigenetic regulator of plasticity and memory. Thus, we hypothesize that PARP-1 may be altered in postmortem hippocampus of individuals with AD compared to age-matched controls without neurologic disease. We found a reduced level of PARP-1 nucleolar immunohistochemical staining in hippocampal pyramidal cells in AD. Nucleolar PARP-1 staining ranged from dispersed and less intense to entirely absent in AD compared to the distinct nucleolar localization in hippocampal pyramidal neurons in controls. In cases of AD, the percentage of hippocampal pyramidal cells with nucleoli that were positive for both PARP-1 and the nucleolar marker fibrillarin was significantly lower than in controls. PARP-1 nucleolar expression emerges as a sensitive marker of functional changes in AD and suggests a novel role for PARP-1 dysregulation in AD pathology.

Indexed as

Epigenesis, GeneticAdultAgedAged, 80 and overAlzheimer DiseaseCell NucleolusChromosomal Proteins, Non-HistoneCognitionDNA, RibosomalFemaleHippocampusHumansMalePoly (ADP-Ribose) Polymerase-1Pyramidal CellsChromosomal Proteins, Non-HistoneDNA, RibosomalfibrillarinPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1

Identifiers

PMID27034851
PMCPMC4789469
OpenAlexW2292736632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.